Skip to content

Study · Animal study (in vivo) · mouse · 2025

7 results

MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism.

Li K, Yang T, Chen F, Lou C, Chen Y, Chen Z, Ye L, Sun X, Liu G, Xie C, Fang J, Hu X and 4 more

Show all authors

Zhu Y, Liu B, He D, Ma H

Free radical biology & medicine1 Oct 2025Cited by 4 (Europe PMC)

PMID41043625 (opens in a new tab)DOI10.1016/j.freeradbiomed.2025.09.056 (opens in a new tab)PepBankPUB-41043625
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In a mouse model of osteoarthritis, MOTS‑c delayed articular cartilage degeneration and ameliorated osteoarthritis progression.

    In plain wordsIn mice with osteoarthritis, MOTS‑c slowed cartilage breakdown and disease progression.

    Peptide
    MOTS-c
    Outcome
    DecreaseArticular cartilage degeneration in murine osteoarthritis
    Study

    mousen: not reported in source

    murine osteoarthritis model
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Analysis of imaging and histopathological results revealed that MOTS-c can effectively delay the degeneration of articular cartilage and ameliorate the progression of osteoarthritis.
    1 context sentence
    Summary · context
    We validated the in vivo efficacy of MOTS-c by establishing a murine osteoarthritis model.
  2. 02LabIn vitro (cells)Efficacy outcome

    In chondrocytes, MOTS‑c inhibited expression of inflammatory factors.

    In plain wordsIn lab cartilage cells, MOTS‑c reduced inflammatory signals.

    Peptide
    MOTS-c
    Outcome
    DecreaseInflammatory factor expression in chondrocytes
    Study

    n: not reported in source

    chondrocytes
    Outcome group
    Inflammation markers · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MOTS-c can not only effectively inhibit the expression of inflammatory factors
  3. 03LabIn vitro (cells)Efficacy outcome

    In chondrocytes, MOTS‑c promoted expression of major components of the extracellular matrix.

    In plain wordsIn lab cartilage cells, MOTS‑c increased the main building blocks of cartilage matrix.

    Peptide
    MOTS-c
    Outcome
    IncreaseExtracellular matrix component expression
    Study

    n: not reported in source

    chondrocytes
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Our research demonstrates that MOTS-c can not only effectively inhibit the expression of inflammatory factors but also promote the expression of major components of the extracellular matrix (ECM) and suppress the production of matrix metalloproteinases.
  4. 04LabIn vitro (cells)Efficacy outcome

    In chondrocytes, MOTS‑c suppressed production of matrix metalloproteinases.

    In plain wordsIn lab cartilage cells, MOTS‑c reduced enzymes that break down cartilage.

    Peptide
    MOTS-c
    Outcome
    DecreaseMatrix metalloproteinase production
    Study

    n: not reported in source

    chondrocytes
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Our research demonstrates that MOTS-c can not only effectively inhibit the expression of inflammatory factors but also promote the expression of major components of the extracellular matrix (ECM) and suppress the production of matrix metalloproteinases.
  5. 05LabIn vitro (cells)Mechanism

    In chondrocytes, exogenous MOTS‑c supplementation improved mitochondrial dysfunction.

    In plain wordsIn lab cartilage cells, MOTS‑c improved mitochondrial function.

    Peptide
    MOTS-c
    Outcome
    DecreaseMitochondrial dysfunction in chondrocytes
    Study

    n: not reported in source

    chondrocytes
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exogenous supplementation of MOTS-c improves mitochondrial dysfunction
  6. 06LabIn vitro (cells)Mechanism

    In chondrocytes, exogenous MOTS‑c supplementation inhibited inflammasome activation and rescued chondrocyte pyroptosis.

    In plain wordsIn lab cartilage cells, MOTS‑c reduced an inflammatory form of cell death.

    Peptide
    MOTS-c
    Outcome
    DecreaseChondrocyte pyroptosis
    Study

    n: not reported in source

    chondrocytes
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    inhibits the activation of inflammatory bodies and rescues chondrocyte pyroptosis, thereby regulating the metabolic balance of extracellular matrix (ECM).
  7. 07LabIn vitro (cells)Mechanism

    In LPS-stimulated chondrocytes, MOTS‑c acted on oxidative stress and pyroptosis through the Nrf2/TXNIP/NLRP3 axis.

    In plain wordsIn lab cartilage cells, MOTS‑c reduced stress-induced damage through the Nrf2/TXNIP/NLRP3 pathway.

    Peptide
    MOTS-c
    Outcome
    Not applicableNrf2/TXNIP/NLRP3 axis in LPS-induced chondrocyte injury
    Study

    n: not reported in source

    chondrocytes
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistically, MOTS-c plays a key role in LPS-induced oxidative stress and chondrocyte pyroptosis through the Nrf2/TXNIP/NLRP3 axis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.